These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37015029)

  • 41. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
    Schulte N; Li M; Zhan T; Dreikhausen L; Sollors J; Antoni C; Diehl S; Schoenberg SO; Rahbari N; Reissfelder C; Giordano FA; Ebert MP; Teufel A
    Z Gastroenterol; 2020 Aug; 58(8):773-777. PubMed ID: 32785913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
    J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.
    Pinato DJ; D'Alessio A; Fulgenzi CAM; Schlaak AE; Celsa C; Killmer S; Blanco JM; Ward C; Stikas CV; Openshaw MR; Acuti N; Nteliopoulos G; Balcells C; Keun HC; Goldin RD; Ross PJ; Cortellini A; Thomas R; Young AM; Danckert N; Tait P; Marchesi JR; Bengsch B; Sharma R
    Clin Cancer Res; 2024 Jun; 30(11):2433-2443. PubMed ID: 38578610
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma.
    Allaire M; Avila MA
    Liver Int; 2024 Jun; 44(6):1276-1277. PubMed ID: 38775365
    [No Abstract]   [Full Text] [Related]  

  • 47. Ramucirumab and other new systemic therapies for hepatocellular carcinoma: still uncovered the problem of Child-Pugh B patients.
    Wilhelmi M
    Chin Clin Oncol; 2021 Jun; 10(3):33. PubMed ID: 33894701
    [No Abstract]   [Full Text] [Related]  

  • 48. Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of "drug class change".
    Saitta C; Cabibbo G
    Dig Liver Dis; 2023 Jul; 55(7):831-832. PubMed ID: 37137807
    [No Abstract]   [Full Text] [Related]  

  • 49. A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies.
    Bévant K; Coulouarn C
    EBioMedicine; 2020 Apr; 54():102737. PubMed ID: 32268278
    [No Abstract]   [Full Text] [Related]  

  • 50. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
    Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
    Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
    Rizzo A; Ricci AD; Brandi G
    Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
    Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
    Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Ramucirumab
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
    Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
    Ryoo BY; Merle P; Kulkarni AS; Cheng AL; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Daniele B; Norquist JM; Chen E; Siegel AB; Zhu AX; Finn RS; Kudo M
    Cancer; 2021 Mar; 127(6):865-874. PubMed ID: 33231873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study-Should we extend the boundaries?
    Gulati P; Taneja S; Duseja A; Singh V
    Hepatology; 2022 Oct; 76(4):E80-E81. PubMed ID: 35503726
    [No Abstract]   [Full Text] [Related]  

  • 58. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability.
    Ando Y; Yamauchi M; Suehiro Y; Yamaoka K; Kosaka Y; Fuji Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Takahashi S; Tsuge M; Hiramatsu A; Imamura M; Chayama K; Aikata H
    Clin J Gastroenterol; 2020 Oct; 13(5):867-872. PubMed ID: 32020539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
    Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.
    Ma X; Hui H; Jin Y; Dong D; Liang X; Yang X; Tan K; Dai Z; Cheng Z; Tian J
    Biomaterials; 2016 May; 87():46-56. PubMed ID: 26897539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.